Media coverage about Bruker (NASDAQ:BRKR) has trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bruker earned a news impact score of 0.19 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.334529633477 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s scoring:
- Teacher Retirement System of Texas Buys 28,803 Shares of Bruker Co. (BRKR) (americanbankingnews.com)
- Bruker Co. (BRKR) Shares Sold by London Co. of Virginia (americanbankingnews.com)
- Bruker Names Burkhard Prause, President of Bruker Energy & Supercon Technologies (BEST), an Executive Officer of Bruker Corporation (finance.yahoo.com)
- $418.40 Million in Sales Expected for Bruker Co. (BRKR) This Quarter (americanbankingnews.com)
- Zacks: Analysts Expect Bruker Co. (BRKR) Will Announce Earnings of $0.25 Per Share (americanbankingnews.com)
BRKR has been the subject of a number of research reports. JPMorgan Chase & Co. raised shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price for the company in a report on Friday, November 3rd. Citigroup upped their target price on shares of Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Bank of America raised shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price for the company in a report on Friday, November 3rd. Zacks Investment Research raised shares of Bruker from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Wednesday, November 8th. Finally, Cowen reaffirmed a “hold” rating and issued a $35.00 target price on shares of Bruker in a report on Thursday, December 21st. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $32.62.
Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.02. The firm had revenue of $530.50 million during the quarter, compared to analysts’ expectations of $506.74 million. Bruker had a net margin of 4.45% and a return on equity of 26.58%. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.46 earnings per share. equities research analysts predict that Bruker will post 1.37 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 23rd. Investors of record on Tuesday, March 6th will be issued a dividend of $0.04 per share. The ex-dividend date of this dividend is Monday, March 5th. This represents a $0.16 annualized dividend and a yield of 0.54%. Bruker’s dividend payout ratio is currently 17.20%.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.